Merck, Inc.
Pembrolizumab/Vibostolimab Coformulation (MK-7684A) or Pembrolizumab/Vibostolimab Coformulation Plus Docetaxel Versus Docetaxel for Metastatic Non Small Cell Lung Cancer (NSCLC) With Progressive Disease After Platinum Doublet Chemotherapy and Immunotherapy (MK-7684A-002, KEYVIBE-002)
- Conditions
- Interventions
- First Posted Date
- 2021-01-26
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 255
- Registration Number
- NCT04725188
- Locations
- 🇺🇸
Cedars-Sinai Medical Center ( Site 2522), Los Angeles, California, United States
🇺🇸University of Maryland ( Site 2528), Baltimore, Maryland, United States
🇧🇪UZ Brussel ( Site 0336), Brussels, Bruxelles-Capitale, Region De, Belgium
Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)-China Extension Study
- First Posted Date
- 2021-01-20
- Last Posted Date
- 2024-10-04
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 201
- Registration Number
- NCT04716933
- Locations
- 🇨🇳
Fujian Provincial Cancer Hospital ( Site 0102), Fuzhou, Fujian, China
🇨🇳Cancer Hospital Affiliated to Xinjiang Medical University ( Site 0110), Urumuqi, Xinjiang, China
🇨🇳The First Affiliated Hospital of Wenzhou Medical University ( Site 0124), Wen Zhou, Zhejiang, China
Safety and Immunogenicity of Extended 2-dose Regimens of 9-valent Human Papillomavirus (9vHPV) Vaccine (V503-069)
- Conditions
- Interventions
- First Posted Date
- 2021-01-13
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 700
- Registration Number
- NCT04708041
- Locations
- 🇲🇽
CAIMED México ( Site 0207), Mexico City, Distrito Federal, Mexico
🇵🇱Gravita Diagnostyka i Leczenie Nieplodnosci ( Site 0555), Lodz, Lodzkie, Poland
🇵🇱ALERGO-MED Specjalistyczna Przychodnia Lekarska ( Site 0557), Tarnow, Malopolskie, Poland
Pembrolizumab Plus Lenvatinib for First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (1L nccRCC) (MK-3475-B61)
- Conditions
- Interventions
- First Posted Date
- 2021-01-11
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 152
- Registration Number
- NCT04704219
- Locations
- 🇺🇸
Comprehensive Cancer Centers of Nevada ( Site 0010), Las Vegas, Nevada, United States
🇺🇦Chernihiv Medical Center of Modern Oncology ( Site 0509), Chernihiv, Chernihivska Oblast, Ukraine
🇷🇺Russian Scientific Center of Radiology-Russian Scientific Center of Radiology ( Site 0602), Moscow, Moskva, Russian Federation
Substudy 02D: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Melanoma Brain Metastasis (MK-3475-02D/KEYMAKER-U02)
- Conditions
- Interventions
- First Posted Date
- 2021-01-07
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 300
- Registration Number
- NCT04700072
- Locations
- 🇺🇸
The Angeles Clinic and Research Institute ( Site 4009), Los Angeles, California, United States
🇺🇸UCLA Hematology & Oncology ( Site 4004), Los Angeles, California, United States
🇺🇸Martha Morehouse Tower ( Site 4020), Columbus, Ohio, United States
Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)
- Conditions
- Interventions
- First Posted Date
- 2021-01-07
- Last Posted Date
- 2024-12-24
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 808
- Registration Number
- NCT04700124
- Locations
- 🇯🇵
Gifu University Hospital ( Site 1513), Gifu, Japan
🇷🇺Volgograd Regional Uronephrological Center ( Site 0870), Volzhsky, Volgogradskaya Oblast, Russian Federation
🇺🇦Municipal Non-profit Enterprise of Kharkiv Regional Council RCSDRPP ( Site 0965), Kharkiv, Kharkivska Oblast, Ukraine
Study of a Single Intravenous (IV) Dose of MK-3402 in Participants With Impaired Renal Function and in Healthy Controls (MK-3402-004)
- First Posted Date
- 2020-12-22
- Last Posted Date
- 2022-11-04
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 9
- Registration Number
- NCT04678505
- Locations
- 🇺🇸
Orlando Clinical Research Center ( Site 0001), Orlando, Florida, United States
🇺🇸Prism Clinical Research, LLC ( Site 0002), Saint Paul, Minnesota, United States
Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Nonsmall Cell Lung Cancer (NSCLC) [MK-7902-007/E7080-G000-314/LEAP-007] - China Extension Study
- Conditions
- Interventions
- First Posted Date
- 2020-12-21
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 27
- Registration Number
- NCT04676412
- Locations
- 🇨🇳
The First Affiliated Hospital of Anhui Medical University ( Site 0113), Hefei, Anhui, China
🇨🇳Hunan Cancer Hospital ( Site 0104), Changsha, Hunan, China
🇨🇳Anhui Provincial Hospital ( Site 0108), Hefei, Anhui, China
A Study to Investigate the Influence of Hepatic Impairment on MK-8189 Treatment (MK-8189-012)
- First Posted Date
- 2020-12-21
- Last Posted Date
- 2023-10-06
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 14
- Registration Number
- NCT04676425
- Locations
- 🇺🇸
Clinical Pharmacology of Miami ( Site 0001), Miami, Florida, United States
🇺🇸ProSciento Inc. ( Site 0002), Chula Vista, California, United States
Efficacy and Safety of MK-1942 When Added to Stable Antidepressant Therapy in Participants With Treatment-Resistant Depression (TRD) (MK-1942-006)
- First Posted Date
- 2020-12-11
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 99
- Registration Number
- NCT04663321
- Locations
- 🇺🇸
Atlanta Center for Medical Research ( Site 1022), Atlanta, Georgia, United States
🇺🇸Woodland International Research Group ( Site 1017), Little Rock, Arkansas, United States
🇺🇸Institute of Living ( Site 1061), Hartford, Connecticut, United States